Literature DB >> 3729330

In vitro activity of antibiotics alone and in combination against Actinobacillus actinomycetemcomitans.

R Yogev, D Shulman, S T Shulman, W G Glogowski.   

Abstract

The MICs for 90% of the organisms tested (MIC90S) of 11 antibiotics against 24 clinical isolates of Actinobacillus actinomycetemcomitans were determined by the MIC 2000 system. The lowest MIC90S (16 micrograms/ml) were observed with ceftriaxone and rifampin. The next lowest MIC90S were found with cephapirin, tetracycline, and chloramphenicol (3.12 micrograms/ml). The MIC90S of penicillin, ampicillin, ticarcillin, piperacillin, and amikacin were each greater than or equal to 12.5 micrograms/ml. Antibiotic synergy was studied by the killing curve method and was defined as a greater than or equal to 2 log10 reduction in CFU when two antibiotics were used in combination at one-fourth the MBC for each compared with the effect of each antibiotic alone at one-half the MBC. Synergism between rifampin and penicillin, cephapirin, or ceftriaxone was tested for with 12 A. actinomycetemcomitans strains. In 7 of 37 instances, synergism was demonstrated for the combinations rifampin plus ceftriaxone (n = 3) or rifampin plus penicillin (n = 4); in 9 instances, an additive effect was noted, and impaired killing with drug combinations compared with the effect of a single antibiotic was suggested in 4 strains. The majority of strains were indifferent to the combinations. Similarly, variable results were observed when the combination of trimethoprim and cephapirin was tested against eight A. actinomycetemcomitans strains. Our data suggest that rifampin and cephapirin are the most active of the 11 antibiotics studied against A. actinomycetemcomitans. In addition, in vitro synergism between rifampin and other antibiotics or between trimethoprim and cephapirin was not consistently demonstrable.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729330      PMCID: PMC180391          DOI: 10.1128/AAC.29.1.179

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Actinobacillus actinomycetemcomitans and Hemophilus aphrophilus.

Authors:  E O KING; H W TATUM
Journal:  J Infect Dis       Date:  1962 Sep-Oct       Impact factor: 5.226

2.  Brain abscess due to Actinobacillus actinomycetemcomitans.

Authors:  B F Martin; B M Derby; G N Budzilovich; J Ransohoff
Journal:  Neurology       Date:  1967-09       Impact factor: 9.910

3.  Bacterial endocarditis due to Actinobacillus actinomycetemcomitans.

Authors:  R M Vogelzang
Journal:  Arch Intern Med       Date:  1967-07

4.  Systemic infection due to Actinobacillus actinomycetemcomitans.

Authors:  L W Burgher; G W Loomis; F Ware
Journal:  Am J Clin Pathol       Date:  1973-09       Impact factor: 2.493

5.  Urinary tract infection due to Actinobacillus actinomycetemcomitans.

Authors:  T R Townsend; J Y Gillenwater
Journal:  JAMA       Date:  1969-10-20       Impact factor: 56.272

6.  Susceptibility of Bacterium actinomycetem comitans to 45 antibiotics.

Authors:  U Höffler; W Niederau; G Pulverer
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  Infective endocarditis due to Actinobacillus actinomycetemcomitans in a patient with a porcine prosthetic mitral valve.

Authors:  G Lalonde; R Hand
Journal:  Can Med Assoc J       Date:  1980-02-09       Impact factor: 8.262

8.  Infection due to Actinobacillus actinomycetemcomitans and Haemophilus aphrophilus.

Authors:  M I Page; E O King
Journal:  N Engl J Med       Date:  1966-07-28       Impact factor: 91.245

9.  Bacterial endocarditis due to Actinobacillus actinomycetemcomitans.

Authors:  J E Goss; R S Gutin; D W Dickhaus
Journal:  Am J Med       Date:  1967-10       Impact factor: 4.965

10.  Infective endocarditis caused by slow-growing, fastidious, Gram-negative bacteria.

Authors:  J J Ellner; M S Rosenthal; P I Lerner; M C McHenry
Journal:  Medicine (Baltimore)       Date:  1979-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.